Mesothelioma is a devastating cancer that primarily affects the lining of the lungs and abdomen. Once exposed to asbestos, it can take years to develop and after being diagnosed, there are not many options for patients. Since there is not a cure, clinical trials can give people hope and can[…]
From the blog
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours (LuPARP)
Primary Outcome Measures Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: up to 6 months after last treatment cycle ] To assess the number of participants with toxicity of 177Lu-DOTA-TATE in combination with olaparib measured by NCI Common Toxicity Criteria v 5.0 Secondary Outcome Measures TTP [ Time Frame: 3[…]
Opdivo and Yervoy Work Together to Treat Pleural Mesothelioma
Mesothelioma is an aggressive cancer with very few treatment options. Patients have a low survival rate, but there is hope with clinical trials. If a clinical trial is found to be effective, patients could live longer and could eventually be cured. Opdivo and Yervoy are two immunotherapy drugs that are[…]
DuRvalumab With Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma (DREAM3R)
Patients with malignant pleural mesothelioma (MPM) that cannot be surgically removed will receive first-line treatment with standard chemotherapy of pemetrexed and cisplatin. Two-thirds of the participants in the study will be randomly assigned to also receive a new treatment called durvalumab.
Neoadjuvant Chemotherapy Does not Improve Survivability in Pleural Mesothelioma Patients
Neoadjuvant chemotherapy is typically used to shrink tumors before surgery to make it easier to remove them. It has been thought that the combination of drugs and surgery can help patients survive longer, but a study at Duke has found that it does not increase survival in pleural mesothelioma patients.[…]
Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
The purpose of this study is to offer a novel cancer vaccine called poly-ICLC (Hiltonol®) for subjects with malignant pleural mesothelioma by directly injecting the vaccine into the tumor.
Nivolumab to Help Treat Mesothelioma
A new study found that the PD-L1 inhibitor nivolumab is effective in mesothelioma. It was tested on patients and showed that it could be a safe and effective treatment for those whose first line treatments have failed. Nivolumab is an immunotherapy drug that helps the immune system fight cancer cells.[…]
Curcumin Could Soon Be Used to Treat Mesothelioma
Curcumin could soon be used to treat mesothelioma patients. It is a natural compound found in turmeric, a spice commonly found in Asian dishes. This natural compound has been used as an anti-inflammatory alongside other treatments, but it could soon be used as a standard mesothelioma treatment, which is what[…]
First-in-human Study of S-588210 (S-488210+S-488211)
The primary objective is to evaluate the safety and tolerability of S-588210 (S-488210+S-488211) in patients with unresectable recurrent and/or metastatic solid tumors.
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU)
The objective of the study is to induce a meaningful progression-free survival benefit in patients with Malign Pleural Mesothelioma (MPM) after progression on first line standard platinum doublet chemotherapy, by treating with nivolumab and ipilimumab with or without UV1 vaccine.
Skip to content